SCHEMBL1744746

SCHEMBL1744746

Nc1ccc(CO)cc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.68
TSHR P16473 4/20 0.50
ALDH1A1 P00352 2/20 0.48
MAPK1 P28482 1/20 0.48
RECQL P46063 2/20 0.45
HPGD P15428 2/20 0.45
ESR2 Q92731 1/20 0.45
THRB P10828 1/20 0.45
ALOX15 P16050 1/20 0.45
CASP1 P29466 1/20 0.45
HSD17B10 Q99714 1/20 0.45
GAA P10253 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774215 0.83 CYP3A4 (0.63) CYP3A4TSHRALDH1A1MAPK1RECQL
SCHEMBL29707966 0.82 CA12 (0.52) CYP3A4TSHRRECQLHPGDGAA
SCHEMBL216270 0.82 CA12 (0.52) CYP3A4TSHRRECQLHPGDGAA
Fluoride SCHEMBL28825920 0.81 CYP3A4 (0.43) CYP3A4TSHRALDH1A1THRBALOX15
SCHEMBL30097830 0.81 CYP3A4 (1.00) CYP3A4TSHRALDH1A1MAPK1RECQL
SCHEMBL43509 0.81 CYP3A4 (1.00) CYP3A4TSHRALDH1A1MAPK1RECQL
SCHEMBL1170188 0.81 CYP3A4 (0.74) CYP3A4TSHRALDH1A1MAPK1RECQL
SCHEMBL8765734 0.79 CYP3A4 (0.95) CYP3A4TSHRALDH1A1MAPK1RECQL
SCHEMBL879052 0.79 CYP3A4 (0.71) CYP3A4TSHRALDH1A1MAPK1RECQL
Ammonia Solution, Strong SCHEMBL9140534 0.79 CYP3A4 (0.95) CYP3A4TSHRALDH1A1MAPK1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673474-A2 ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2026-01-07 EP disclosed
WO-2024182569-A2 ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-09-06 WO disclosed
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds IDEAYA BIOSCIENCES, INC. (US) 2023-02-21 US disclosed
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds IDEAYA BIOSCIENCES, INC. (US) 2023-02-21 US disclosed
US-20220227780-A1 DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS IDEAYA BIOSCIENCES, INC. 2022-07-21 US disclosed
WO-2019067442-A1 DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS IDEAYA BIOSCIENCES, INC. (US) 2019-04-04 WO disclosed
WO-2019067442-A1 DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS IDEAYA BIOSCIENCES, INC. (US) 2019-04-04 WO disclosed
US-9643961-B2 Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities ALMIRALL, S.A. (ES) 2017-05-09 US disclosed
EP-2569308-B1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL SA (ES) 2016-11-23 EP disclosed
US-20160264557-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL, S.A. (ES) 2016-09-15 US disclosed
US-9315463-B2 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities ALMIRALL, S.A. (ES) 2016-04-19 US disclosed
CN-102892765-B Cyclohexylamine derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonist activity ALMIRALL SA 2015-04-29 CN disclosed
US-20130281415-A9 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL, S.A. (ES) 2013-10-24 US disclosed
EP-2569308-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES Almirall S.A. (ES) 2013-03-20 EP disclosed
US-20130053359-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES PRAT QUINONES MARIA (ES) 2013-02-28 US disclosed
WO-2011141180-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL, S.A. (ES) 2011-11-17 WO disclosed
EP-2386555-A1 New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities Almirall, S.A. (ES) 2011-11-16 EP disclosed
US-20110254356-A1 Wheel Bearing Apparatus Incorporated With A Wheel Speed Detecting Apparatus NTN CORPORATION (JP) 2011-10-20 US disclosed
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264557-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ADRB2, CHRM2, CHRM3 CYP3A4 378/4885TSHR 240/4885ALDH1A1 1707/4885
US-20130281415-A9 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ADRB2, CHRM2, CHRM3 CYP3A4 428/4885TSHR 238/4885ALDH1A1 1849/4885
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds DHFR, CYC1, CYCS CYP3A4 632/4885TSHR 229/4885ALDH1A1 700/4885
US-20130053359-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ADRB2, CHRM2, CHRM3 CYP3A4 503/4885TSHR 251/4885ALDH1A1 1932/4885
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 CYP3A4 3044/4885TSHR 1728/4885ALDH1A1 731/4885
US-20220227780-A1 DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS DHFR, CYC1, CYCS CYP3A4 632/4885TSHR 229/4885ALDH1A1 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.